Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Apple Turns 50: From Garage Startup to AI Crossroads 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
LOS ANGELES, July 17, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq:NTRP) for possible violations of federal securities laws from January 7, 2016 through April 28, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Neurotrope shares during the Class Period should contact the firm by the July 17, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet, and until a class is certified, you are not considered represented by an attorney. You may choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information, regarding the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” The underlying trial data contradicted these representations, as the top-line data relating to the 20-microgram dose of Bryostatin-1 failed to produce results that were statistically significant. Also, Neurotrope failed to disclose statements regarding the efficacy of the 40-microgram dose with regard to its primary and secondary endpoints. Upon release of this news, the Company’s stock price dropped materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
